rss
J Neurol Neurosurg Psychiatry 84:657-665 doi:10.1136/jnnp-2012-302441
  • Movement disorders
  • Research paper

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease

Open Access
  1. 1Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
  2. 2Department of Clinical Neuroscience, University of Cambridge Medical School, Addenbrooke's Hospital, Cambridge UK
  3. 3Department of Neurosurgery, University of Cambridge Medical School, Addenbrooke's Hospital, Cambridge UK
  4. 4Department of Psychiatry, University of Cambridge Medical School, Addenbrooke's Hospital, Cambridge UK
  5. 5Department of Obstetrics and Gynaecology, University of Cambridge Medical School, Addenbrooke's Hospital, Cambridge, UK
  6. 6Centre for Neuroscience, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
  7. 7Brain Repair Group, School of Biosciences and Medicine, Cardiff University, Wales, UK
  1. Correspondence to Dr Roger Barker, Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Cambridge CB2 0PY, UK; rab46{at}cam.ac.uk
  • Received 26 April 2012
  • Revised 18 September 2012
  • Accepted 18 December 2012
  • Published Online First 23 January 2013

Abstract

Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disease involving progressive motor, cognitive and behavioural decline, leading to death approximately 20 years after motor onset. The disease is characterised pathologically by an early and progressive striatal neuronal cell loss and atrophy, which has provided the rationale for first clinical trials of neural repair using fetal striatal cell transplantation. Between 2000 and 2003, the ‘NEST-UK’ consortium carried out bilateral striatal transplants of human fetal striatal tissue in five HD patients. This paper describes the long-term follow up over a 3–10-year postoperative period of the patients, grafted and non-grafted, recruited to this cohort using the ‘Core assessment program for intracerebral transplantations-HD’ assessment protocol. No significant differences were found over time between the patients, grafted and non-grafted, on any subscore of the Unified Huntington's Disease Rating Scale, nor on the Mini Mental State Examination. There was a trend towards a slowing of progression on some timed motor tasks in four of the five patients with transplants, but overall, the trial showed no significant benefit of striatal allografts in comparison with a reference cohort of patients without grafts. Importantly, no significant adverse or placebo effects were seen. Notably, the raclopride positron emission tomography (PET) signal in individuals with transplants, indicated that there was no obvious surviving striatal graft tissue. This study concludes that fetal striatal allografting in HD is safe. While no sustained functional benefit was seen, we conclude that this may relate to the small amount of tissue that was grafted in this safety study compared with other reports of more successful transplants in patients with HD.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Open Access

Podcasts
Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article